Informations

Editor’s Note: If antimicrobial drugs are the “express train” to cure, then antimicrobial susceptibility testing information is the “map” for accurate navigation. For a long time, China’s antimicrobial “map” has…

Colorectal cancer ranks as the second most prevalent malignancy in China and represents the most common type of gastrointestinal cancer. In recent years, there has been a rapid increase in both incidence and mortality rates. With continuous innovations in relevant diagnostic and therapeutic technologies such as immunotherapy and radiotherapy, the efficacy of treatments for patients…

To further explore the advances in clinical and pathological diagnosis, treatment, and translational medicine research in lymphoma, the “2024 Nanjing Lymphoma Forum” was held in Nanjing from May 11-12, 2024. At the forum, Professor Tongyu Lin from Sun Yat-sen University Cancer Center and Sichuan Cancer Hospital delivered an academic report titled “Progress in Lymphoma Diagnosis…

As the population continues to age, the incidence of hematologic malignancies in the elderly has been rising, presenting new challenges for clinical treatment. From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was held in Glasgow, UK. The conference focused on the latest advancements in stem…

From April 14 to 17, 2024, the 50th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting was grandly held in Glasgow, UK, a city renowned for its historical significance. This year marks the 50th anniversary of EBMT, and the event gathered leading figures in the field of hematopoietic stem cell transplantation and over…

Patients with chronic lymphocytic leukemia (CLL) are susceptible to infections due to impaired humoral and cellular immunity. Bruton’s tyrosine kinase inhibitors (BTKi) are crucial in CLL treatment. Recent studies have shown an increased incidence of invasive fungal diseases (IFDs) (0.5% to 12.1%) in patients receiving BTKi treatment, particularly central nervous system infections. From April 14th…

In January 2023, a study led by Professor Jianxiang Wang from Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College was published…

In January 2023, Professor Jianmin Wang from Department of Hematology, Shanghai Changhai Hospital published a commentary on Blood Science. The title of the study is “Big stride in gene therapy for hemophilia B in China”. This article reviewed the development of treatment of hemophilia B (HB) in China, and the translational potential of gene therapy…